

Chris Verslype

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9027914/publications.pdf>

Version: 2024-02-01

183
papers

15,002
citations

61857

43
h-index

18606

119
g-index

183
all docs

183
docs citations

183
times ranked

17148
citing authors

#	ARTICLE	IF	CITATIONS
1	One-stage laparoscopic parenchymal sparing liver resection for bilobar colorectal liver metastases: safety, recurrence patterns and oncologic outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 1018-1026.	1.3	5
2	Combined liver-intestinal and multivisceral transplantation for neuroendocrine tumors extending beyond the liver: A systematic literature review. <i>Transplantation Reviews</i> , 2022, 36, 100678.	1.2	4
3	Segmentation-guided multi-modal registration of liver images for dose estimation in SIRT. <i>EJNMMI Physics</i> , 2022, 9, 3.	1.3	1
4	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>European Journal of Cancer</i> , 2022, 167, 1-12.	1.3	43
5	Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. <i>Cancers</i> , 2022, 14, 129.	1.7	21
6	Potential importance of early treatment of SARS-CoV-2 infection in intestinal transplant patient: A case report. <i>World Journal of Transplantation</i> , 2022, 12, 72-78.	0.6	0
7	Laparoscopic liver resection for colorectal liver metastases: retrospective analysis of prognostic factors and oncological outcomes in a single-center cohort. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2399-2414.	0.8	2
8	The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2022, 168, 80-90.	1.3	12
9	Transarterial drug delivery for liver cancer: numerical simulations and experimental validation of particle distribution in patient-specific livers. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 409-422.	2.4	11
10	Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 297-297.	0.8	4
11	ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	1.4	7
12	Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4074-4074.	0.8	1
13	Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4100-4100.	0.8	17
14	Liver-Related and Cardiovascular Outcome of Patients Transplanted for Nonalcoholic Fatty Liver Disease: A European Single-Center Study. <i>Transplantation Proceedings</i> , 2021, 53, 1674-1681.	0.3	5
15	Mimicry of an acute pseudocyst by a gastrointestinal duplication cyst in a 14-year-old boy. <i>Endoscopy</i> , 2021, , .	1.0	0
16	P-84: Mixed Physiological and Non-physiological Portal Inflow as an Alternative to Multivisceral Transplantation in a Patient with Diffuse Splanchnic Thrombosis. <i>Transplantation</i> , 2021, 105, S93-S93.	0.5	0
17	Laparoscopic liver resection for colorectal liver metastases " short- and long-term outcomes: A systematic review. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 732-757.	0.8	5
18	Recanalization of portal axis after cavoportal hemitransposition in a liver transplant recipient with complete splanchnic thrombosis. <i>Pediatric Transplantation</i> , 2021, 25, e14097.	0.5	2

#	ARTICLE	IF	CITATIONS
19	933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study. <i>Annals of Oncology</i> , 2021, 32, S819.	0.6	1
20	Residual Splenic Volume after Main Splenic Artery Embolization is Independent of the Underlying Disease. <i>Journal of the Belgian Society of Radiology</i> , 2021, 105, 19.	0.1	3
21	Donor Hepatectomy and Implantation Time Are Associated With Early Complications After Liver Transplantation: A Single-center Retrospective Study. <i>Transplantation</i> , 2021, 105, 1030-1038.	0.5	23
22	Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11770.	1.8	7
23	Laparoscopic liver resection for liver tumours in proximity to major vasculature: A single-center comparative study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 539-547.	0.5	10
24	Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. <i>Surgical Oncology</i> , 2020, 33, 231-238.	0.8	25
25	Inflammation-Based Index and ⁶⁸ Ga-DOTATOC PET-derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with ⁹⁰ Y-DOTATOC. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1014-1020.	2.8	28
26	Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 727-732.	0.8	10
27	Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report. <i>BMC Gastroenterology</i> , 2020, 20, 324.	0.8	0
28	<p></p>Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6907-6916.	1.0	13
29	1003P Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240. <i>Annals of Oncology</i> , 2020, 31, S696-S697.	0.6	1
30	Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. <i>Translational Oncology</i> , 2020, 13, 100743.	1.7	34
31	[¹⁸ F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [⁶⁸ Ga]Ga-DOTATATE in neuroendocrine tumour patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3033-3046.	3.3	59
32	Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of ¹⁷⁷ Lu-DOTATATE PRRT. <i>Acta Oncologica</i> , 2020, 59, 644-651.	0.8	7
33	DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. <i>Clinical Epigenetics</i> , 2020, 12, 27.	1.8	64
34	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with ¹⁷⁷ Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382.	3.3	79
35	Could Autoimmune Disease Contribute to the Abscopal Effect in Metastatic Hepatocellular Carcinoma?. <i>Hepatology</i> , 2020, 72, 1152-1154.	3.6	6
36	Whole liver segmentation based on deep learning and manual adjustment for clinical use in SIRT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2742-2752.	3.3	36

#	ARTICLE	IF	CITATIONS
37	Quantitative comparison of pre-treatment predictive and post-treatment measured dosimetry for selective internal radiation therapy using cone-beam CT for tumor and liver perfusion territory definition. <i>EJNMMI Research</i> , 2020, 10, 94.	1.1	7
38	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019, 68, 1065-1075.	6.1	195
39	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 1164-1174.	1.8	249
40	Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2398-2399.	3.3	30
41	Mass migration to Europe: an opportunity for elimination of hepatitis B virus?. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 315-323.	3.7	25
42	<i>Candida albicans</i> tenosynovitis of the hand. <i>Rheumatology</i> , 2019, 58, 1889.	0.9	2
43	Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. <i>Nature</i> , 2019, 566, 403-406.	13.7	326
44	YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role. <i>International Journal of Molecular Sciences</i> , 2019, 20, 638.	1.8	44
45	Age Matching of Elderly Liver Grafts With Elderly Recipients Does Not Have a Synergistic Effect on Long-term Outcomes When Both Are Carefully Selected. <i>Transplantation Direct</i> , 2019, 5, e342.	0.8	10
46	Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells. <i>Cancers</i> , 2019, 11, 1984.	1.7	29
47	Thrombosis of a portal vein aneurysm: a case report with literature review. <i>Acta Clinica Belgica</i> , 2019, 74, 115-120.	0.5	5
48	Laparoscopic right posterior sectionectomy: single-center experience and technical aspects. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 21-29.	0.8	15
49	Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 765-779.	0.0	6
50	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	5.1	51
51	Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. <i>Investigational New Drugs</i> , 2018, 36, 683-695.	1.2	75
52	Pre-operative trans-catheter arterial chemo-embolization increases hepatic artery thrombosis after liver transplantation - a retrospective study. <i>Transplant International</i> , 2018, 31, 71-81.	0.8	11
53	Ageing in Liver Transplantation. <i>Transplantation</i> , 2018, 102, S125.	0.5	0
54	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	5.1	1,816

#	ARTICLE	IF	CITATIONS
55	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. <i>International Journal of Cancer</i> , 2018, 143, 2053-2064.	2.3	76
56	Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature. <i>International Journal of Dermatology</i> , 2018, 57, 1075-1079.	0.5	13
57	Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1716-1726.	0.9	6
58	Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4020-4020.	0.8	9
59	Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 european patientsâ€™ The ENETS registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4095-4095.	0.8	4
60	KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 209-209.	0.8	30
61	Long-term clinical and radiological outcome of endovascular embolization of pancreatitis-related pseudoaneurysms. <i>Acta Radiologica</i> , 2017, 58, 316-322.	0.5	23
62	Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results. <i>Radiology and Oncology</i> , 2017, 51, 74-80.	0.6	8
63	Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial. <i>Journal of Hepatology</i> , 2017, 66, S12-S13.	1.8	7
64	Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein Response. <i>Translational Oncology</i> , 2017, 10, 59-69.	1.7	37
65	Implementation and Use of a Patient Symptom Diary During Chemotherapy: A Mixed-Methods Evaluation of the Nurse Perspective. <i>Oncology Nursing Forum</i> , 2017, 44, E213-E222.	0.5	4
66	A new intraductal radiofrequency ablation device for inoperable biliopancreatic tumors complicated by obstructive jaundice: the IGNITE-1 study. <i>Endoscopy</i> , 2017, 49, 977-982.	1.0	41
67	Use of a symptom diary during chemotherapy: A mixed-methods evaluation of the patient perspective. <i>European Journal of Oncology Nursing</i> , 2017, 31, 37-45.	0.9	16
68	Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1882-1890.	0.9	17
69	Usefulness of the single-operator cholangioscopy system SpyGlass in biliary disease: a single-center prospective cohort study and aggregated review. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 2223-2232.	1.3	73
70	Expanded polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunts in cirrhotic patients: Long-term patency and clinical outcome results. <i>European Radiology</i> , 2017, 27, 1795-1803.	2.3	26
71	Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-343.	0.8	17
72	A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2016, 9, 139-146.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study. <i>Endoscopy</i> , 2016, 48, 1016-1022.	1.0	10
74	Interfering with epigenetics in hepatocellular carcinoma: Out of the shelter?. <i>Journal of Hepatology</i> , 2016, 65, 243-244.	1.8	3
75	New observation of sialuria prompts detection of liver tumor in previously reported patient. <i>Molecular Genetics and Metabolism</i> , 2016, 118, 92-99.	0.5	4
76	Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival. <i>Acta Oncol</i> , 2016, 55, 486-495.	0.8	22
77	Tenckhoff tunneled peritoneal catheter placement in the palliative treatment of malignant ascites: technical results and overall clinical outcome. <i>Radiology and Oncology</i> , 2016, 50, 197-203.	0.6	26
78	Percutaneous shunt reduction for the management of TIPS-induced acute liver decompensation: A follow-up study. <i>Annals of Hepatology</i> , 2016, 15, 911-917.	0.6	8
79	A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. <i>Anticancer Research</i> , 2016, 36, 713-9.	0.5	66
80	DNA methylation in hepatocellular carcinoma: what is the use?. <i>Hepatic Oncology</i> , 2015, 2, 321-323.	4.2	1
81	O-013 A global risk gene score predicts early and late tumor recurrence after resection of hepatocellular carcinoma. <i>Annals of Oncology</i> , 2015, 26, iv112.	0.6	0
82	Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial <sc>SORAMIC</sc>. <i>Liver International</i> , 2015, 35, 620-626.	1.9	74
83	Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series. <i>JIMD Reports</i> , 2015, 25, 77-81.	0.7	39
84	Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4102-4102.	0.8	10
85	Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 344-344.	0.8	13
86	Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. <i>Gut</i> , 2014, 63, 674-685.	6.1	221
87	The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona. <i>Annals of Oncology</i> , 2014, 25, ii1-ii4.	0.6	3
88	The effectiveness of selective internal radiation therapy in challenging cases of liver-predominant unresectable hepatocellular carcinoma. <i>Future Oncology</i> , 2014, 10, 17-27.	1.1	10
89	Chemoembolization for Hepatocellular Carcinoma: 1-Month Response Determined with Apparent Diffusion Coefficient Is an Independent Predictor of Outcome. <i>Radiology</i> , 2014, 270, 747-757.	3.6	56
90	Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients. <i>Clinical Cancer Research</i> , 2014, 20, 2159-2168.	3.2	31

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetic changes after placement of a transjugular intrahepatic portosystemic shunt. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 377-378.	0.8	3
92	Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1141-57.	3.3	25
93	Su1667 Usefulness of the Single-Operator Cholangioscopy-System SPYGLASS in Biliopancreatic Diagnostic and Therapeutic Interventions: a Single-Center Cohort Study. <i>Gastrointestinal Endoscopy</i> , 2014, 79, AB359-AB360.	0.5	0
94	Transcatheter Arterial Chemoembolization with Doxorubicin-Eluting Superabsorbent Polymer Microspheres in the Treatment of Hepatocellular Carcinoma: Midterm Follow-up. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 248-255.e1.	0.2	13
95	Clinical Approaches of Emergencies in Neuroendocrine Tumors. , 2014, , 221-236.		0
96	Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (SORAMIC).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4154-TPS4154.	0.8	0
97	Safety and activity of ziv-aflibercept in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with colorectal cancer previously treated with irinotecan: Results from a phase 1 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14510-e14510.	0.8	0
98	Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 3865-3876.	1.3	56
99	Automated low flow pump system for the treatment of refractory ascites: A multi-center safety and efficacy study. <i>Journal of Hepatology</i> , 2013, 58, 922-927.	1.8	114
100	Prospective Comparison of Hydrogel-coated Microcoils versus Fibered Platinum Microcoils in the Prophylactic Embolization of the Gastroduodenal Artery before Yttrium-90 Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 797-803.	0.2	22
101	Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. <i>Cancer Letters</i> , 2013, 329, 74-83.	3.2	154
102	Significant impact of transient deterioration of renal function on dosimetry in PRRT. <i>Annals of Nuclear Medicine</i> , 2013, 27, 74-77.	1.2	9
103	Advanced unresectable hepatocellular carcinoma. <i>Current Opinion in Oncology</i> , 2013, 25, 409-416.	1.1	17
104	Heterozygous Δ 1-antitrypsin Z allele mutation in presumed healthy donor livers used for transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1335-1339.	0.8	16
105	Influence of Time Delay on the Estimated Lung Shunt Fraction on 99mTc-Labeled MAA Scintigraphy for 90Y Microsphere Treatment Planning. <i>Clinical Nuclear Medicine</i> , 2013, 38, 940-942.	0.7	25
106	Treatment of non-alcoholic fatty liver disease: can we already face the epidemic?. <i>Acta Gastro-Enterologica Belgica</i> , 2013, 76, 200-9.	0.4	5
107	The Impact of a Transjugular Intrahepatic Portosystemic Shunt on the Pharmacokinetics of Caspofungin in a Critically Ill Patient. <i>Pharmacology</i> , 2012, 90, 247-250.	0.9	11
108	Transcatheter arterial embolization for iatrogenic hemobilia is a safe and effective procedure. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 905-909.	0.8	29

#	ARTICLE	IF	CITATIONS
109	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AVITA and AVOREN randomised trials. <i>Lancet Oncology</i> , The, 2012, 13, 724-733.	5.1	174
110	Cholestasis-induced pruritus treated with ultraviolet B phototherapy: An observational case series study. <i>Journal of Hepatology</i> , 2012, 57, 637-641.	1.8	50
111	Characterization of a cell culture model for clinically aggressive hepatocellular carcinoma induced by chronic hypoxia. <i>Cancer Letters</i> , 2012, 315, 178-188.	3.2	12
112	Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. <i>Hepatology</i> , 2012, 55, 1876-1888.	3.6	268
113	<i>HNF1B</i> deficiency causes ciliary defects in human cholangiocytes. <i>Hepatology</i> , 2012, 56, 1178-1181.	3.6	26
114	Histology obtained by needle biopsy gives additional information on the prognosis of hepatocellular carcinoma. <i>Hepatology Research</i> , 2012, 42, 990-998.	1.8	17
115	Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4007-4007.	0.8	50
116	Resistance development after long-term sorafenib exposure in hepatocellular cancer cell lines and risk of rebound growth and epithelial to mesenchymal transition.. <i>Journal of Clinical Oncology</i> , 2012, 30, 216-216.	0.8	20
117	Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 261-261.	0.8	22
118	Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (HCC) (SORAMIC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4148-TPS4148.	0.8	1
119	Prospective Study Comparing Different Indirect Methods to Measure Portal Pressure. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 1553-1558.	0.2	38
120	Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 523-537.	1.4	80
121	83 HISTOLOGICAL DIVERSITY IN CHOLANGIOCELLULAR CARCINOMA SUGGESTING DIFFERENT CELLS OF ORIGIN: INTRAHEPATIC PROGENITOR CELLS VERSUS HILAR MUCIN PRODUCING CELLS. <i>Journal of Hepatology</i> , 2011, 54, S37.	1.8	3
122	178 A PROSPECTIVE STUDY COMPARING THE DIFFERENT INDIRECT METHODS TO MEASURE PORTAL PRESSURE. <i>Journal of Hepatology</i> , 2011, 54, S76-S77.	1.8	0
123	Caroli disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 578-585.	0.8	25
124	Giant liver hemangioma. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 438-443.	0.8	31
125	Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 564-571.	0.8	30
126	An update on cholangiocarcinoma associated with primary sclerosing cholangitis. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 236-245.	1.0	23

#	ARTICLE	IF	CITATIONS
127	Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model. <i>European Radiology</i> , 2010, 20, 2372-2380.	2.3	7
128	Alpers syndrome presenting with anatomopathological features of fulminant autoimmune hepatitis. <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 451-451.	1.7	3
129	A Seven-Gene Set Associated with Chronic Hypoxia of Prognostic Importance in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2010, 16, 4278-4288.	3.2	56
130	Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. <i>Gut</i> , 2010, 59, 1561-1569.	6.1	226
131	Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. <i>Acta Pharmacologica Sinica</i> , 2010, 31, 1409-1420.	2.8	150
132	Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 3687-3694.	0.8	377
133	An adult male patient with multiple adenomas and a hepatocellular carcinoma: Mild Glycogen Storage Disease type Ia. <i>Journal of Hepatology</i> , 2010, 53, 213-217.	1.8	40
134	120 A 7 GENE SET ASSOCIATED WITH CHRONIC HYPOXIA OF UNIVERSAL PROGNOSTIC IMPORTANCE IN HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2010, 52, S53.	1.8	0
135	Carcinoid heart disease: Case and literature review. <i>Acta Cardiologica</i> , 2010, 65, 261-264.	0.3	14
136	Cirrhosis and malnutrition: assessment and management. <i>Acta Gastro-Enterologica Belgica</i> , 2010, 73, 510-3.	0.4	2
137	Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2231-2237.	0.8	611
138	Transcatheter Chemoembolization of Unresectable Hepatocellular Carcinoma: Current Knowledge and Future Directions. <i>Digestive Diseases</i> , 2009, 27, 157-163.	0.8	29
139	Quantitation of replication of the HCV genome in human livers with end-stage cirrhosis by strand-specific real-time RT-PCR assays: Methods and clinical relevance. <i>Journal of Medical Virology</i> , 2009, 81, 1569-1575.	2.5	5
140	Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. <i>European Radiology</i> , 2009, 19, 2456-2466.	2.3	163
141	Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease. <i>Journal of Cystic Fibrosis</i> , 2009, 8, 392-399.	0.3	91
142	The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. <i>Acta Gastro-Enterologica Belgica</i> , 2009, 72, 54-8.	0.4	4
143	Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. <i>Hepatology</i> , 2008, 47, 1544-1556.	3.6	332
144	Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. <i>Liver International</i> , 2008, 28, 1370-1380.	1.9	94

#	ARTICLE	IF	CITATIONS
145	Congenital veno-venous malformations of the liver: Widely variable clinical presentations. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, e390-4.	1.4	84
146	Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and <i>in vitro</i> . <i>Hepatology Research</i> , 2008, 38, 1112-1121.	1.8	31
147	Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5225-5232.	0.8	306
148	The RANTES -28 g polymorphism is associated with primary sclerosing cholangitis. <i>Gut</i> , 2007, 56, 891-892.	6.1	4
149	Endovascular Shunt Reduction in the Management of Transjugular Portosystemic Shunt-Induced Hepatic Encephalopathy: Preliminary Experience with Reduction Stents and Stent-Grafts. <i>American Journal of Roentgenology</i> , 2007, 188, 659-664.	1.0	39
150	Lessons Learned in the Management of Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1949-1952.	0.8	33
151	Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. <i>Lancet Oncology</i> , The, 2007, 8, 387-394.	5.1	200
152	Management of Transjugular Intrahepatic Portosystemic Shunt-Induced Refractory Hepatic Encephalopathy with the Parallel Technique: Results of a Clinical Follow-up Study. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 986-992.	0.2	28
153	MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. <i>Liver International</i> , 2007, 27, 329-334.	1.9	81
154	HBx or HCV core gene expression in HepG2 human liver cells results in a survival benefit against oxidative stress with possible implications for HCC development. <i>Chemico-Biological Interactions</i> , 2007, 168, 128-134.	1.7	20
155	Incidence, Diagnosis, and Therapy of Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis. <i>Digestive Diseases and Sciences</i> , 2007, 52, 3123-3135.	1.1	121
156	The diagnostic and therapeutic approach for primary solid liver tumours in adults. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 983-996.	1.0	13
157	Intrahepatische zwangerschapscholestase: nieuwe inzichten in pathogenese en behandeling. <i>Tijdschrift Voor Geneeskunde</i> , 2007, 63, 1190-1197.	0.0	0
158	The Use of Carbon Dioxide Wedged Hepatic Venography to Identify the Portal Vein: Comparison with Direct Catheter Portography with Iodinated Contrast Medium and Analysis of Predictive Factors Influencing Level of Opacification. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 1771-1779.	0.2	32
159	Glypican-3 Expression Distinguishes Small Hepatocellular Carcinomas From Cirrhosis, Dysplastic Nodules, and Focal Nodular Hyperplasia-like Nodules. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1405-1411.	2.1	258
160	Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1311-1319.	0.8	39
161	Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial. <i>Transplant International</i> , 2006, 19, 1000-1005.	0.8	44
162	Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. <i>Liver International</i> , 2006, 26, 1225-1233.	1.9	148

#	ARTICLE	IF	CITATIONS
163	CC-Type chemokine receptor 5-Î”32 mutation protects against primary sclerosing cholangitis. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 272-277.	0.9	25
164	Hepatitis B virus replication causes oxidative stress in HepAD38 liver cells. <i>Molecular and Cellular Biochemistry</i> , 2006, 290, 79-85.	1.4	51
165	Acuut leverfalen: nieuwe bevindingen. <i>Tijdschrift Voor Geneeskunde</i> , 2006, 62, 1-6.	0.0	0
166	Leptomeningeal carcinomatosis associated with oesophageal adenocarcinoma: two case reports and review of the literature. <i>Acta Gastro-Enterologica Belgica</i> , 2006, 69, 377-80.	0.4	2
167	Adjuvant chemotherapy for stage III colon cancer in 2005: where are we now?. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 291-299.	2.2	1
168	Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2005, 43, 358-360.	1.8	39
169	Tolerance of Liver Transplant Patients to Strenuous Physical Activity in High-Altitude. <i>American Journal of Transplantation</i> , 2004, 4, 554-560.	2.6	27
170	Combined 'En Bloc' Liver and Pancreas Transplantation in Patients with Liver Disease and Type 1 Diabetes Mellitus. <i>American Journal of Transplantation</i> , 2004, 4, 1921-1927.	2.6	24
171	Early and long-term clinical and radiological follow-up results of expanded-polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunt procedures. <i>European Radiology</i> , 2004, 14, 1842-50.	2.3	61
172	Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 337-345.	13.9	4,721
173	Expression of hepatitis C virus core protein impairs DNA repair in human hepatoma cells. <i>Cancer Letters</i> , 2004, 209, 197-205.	3.2	26
174	152 A prospective open, single arm, pilot trial to assess the safety and efficacy of orlistat in obese liver transplant patients. <i>Journal of Hepatology</i> , 2004, 40, 51-52.	1.8	1
175	Systemic treatment of pancreatic cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 265-274.	0.8	40
176	Oxidative stress and oval cell accumulation in mice and humans with fatty liver disease. <i>Gastroenterology</i> , 2003, 124, A689.	0.6	0
177	Oxidative Stress and Oval Cell Accumulation in Mice and Humans with Alcoholic and Nonalcoholic Fatty Liver Disease. <i>American Journal of Pathology</i> , 2003, 163, 1301-1311.	1.9	398
178	Progenitor cell activation in alcoholic (ALD) and in non-alcoholic fatty liver disease (NAFLD): An immunohistochemical and ultrastructural study. <i>Journal of Hepatology</i> , 2003, 38, 193.	1.8	9
179	PRIMARY HUMAN HEPATOCYTES ARE PROTECTED AGAINST PROLONGED AND REPEATED EXPOSURE TO ETHANOL BY SILIBININ-DIHEMISUCCINATE. <i>Alcohol and Alcoholism</i> , 2003, 38, 411-414.	0.9	18
180	Ultrastructural visualization of hepatitis C virus components in human and primate liver biopsies. <i>Journal of Hepatology</i> , 2002, 37, 370-379.	1.8	29

#	ARTICLE	IF	CITATIONS
181	The treatment of advanced colorectal cancer: where are we now and where do we go?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2002, 16, 319-330.	1.0	20
182	TTV infection and its relation to serum transaminases in apparently healthy blood donors and in patients with clotting disorders who have been investigated previously for hepatitis C virus and GBV-C/HGV infection in Belgium. Journal of Medical Virology, 2002, 66, 561-6.	2.5	3
183	Pregnancy and liver disease. , 0, , 379-390.		0